Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹203 Cr
verified against source
Revenue YoY
-26%
reported change
EBITDA
₹3.8 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Best Agrolife reported a weak Q3 FY26 with revenue of 202.9 crore, down 26% YoY, due to excessive rainfall and low pest pressure disrupting crop cycles. EBITDA turned positive at 3.8 crore (1.9% margin), improving from a loss last year, but PAT remained a loss of 12.7 crore. The patented portfolio held up relatively well (down only 5%), while generics slumped 48%. Management guided FY26 revenue of 1,300-1,400 crore and expects a return to growth in FY27, targeting 1,500-1,600 crore. Key risks include potential El Niño impact and the conversion of outstanding warrants at a strike price far above the current market price, which could dilute equity if not exercised.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects full-year FY26 revenue between 1,300 and 1,400 crore, implying Q4 run-rate of 200-300 crore.
- For FY27, management targets revenue of 1,500-1,600 crore, driven by patented product growth and stabilization.
- Management expects EBITDA margin to improve to 16-17% in FY27, up from ~11.5% in 9M FY26.
- Management aims to report a profit (no losses) in Q4 FY26, despite softer seasonal demand.
Risks flagged
- Outstanding warrants with exercise price of ~42 rupees (post-split) are far above current market price of ~19 rupees, potentially leading to non-exercise and equity dilution or failed capital raise.
- Potential El Niño conditions could disrupt crop cycles and reduce demand for agrochemicals, impacting revenue recovery plans.
- Interest costs of 50-55 crore annually exceed net profits, raising sustainability concerns if profitability does not improve.
- Non-patent portfolio declined 48% in 9M FY26, indicating potential market share loss as company pivots to patented products.
Key quotes
- Our patent product portfolio continue to perform and our distribution reach remains strong.
- We are in the phase where we are doing marketing more, where we are doing sales force more, where we are expenses more.
- This year would be the worst what we say and the worst will be for us and from next June onwards already we have our plans.
Research modules